A series of studies by Drs. Linda Dwoskin and Michael Bardo demonstrated the preclinical efficacy of novel vesicular monoamine transporter 2 (VMAT2) inhibitors as antagonists of dmethamphetamine self-administration in rats [1] [2] [3] [4] [5] [6] . This is an important finding since there is a lack of FDA-approved medications to treat amphetamine-type stimulant abuse. There are also few if any candidate compounds that show preclinical efficacy as amphetamine antagonists (e.g. [7] ).
tetrabenazine failed to exhibit pharmacological specificity. (±)-Tetrabenazine was equipotent in decreasing self-administration responding for d-methamphetamine and food reinforced responding [2] .
Te novel VMAT2 inhibitors possess a clinically preferential profile since the duration of action as d-methamphetamine antagonists in vivo lasted at least 60 minutes [1] [2] [3] [4] [5] [6] , which is approximately 12-fold longer than the elimination half-life of the prototype VMAT2 inhibitor (±)-tetrabenazine [10] . However, the novel VMAT2 inhibitors need improvement to be useful clinically since they possess relatively low affinity for VMAT2 (Ki values >2,000 nM, see Table 1 ). VMAT2 is a cytoplasmic protein and VMAT2 inhibitors need to penetrate plasma membranes in vivo.
Despite the fact that the novel VMAT2 inhibitors exhibited low affinities for VMAT2, the series of studies by Drs. Dwoskin and Bardo demonstrated the preclinical efficacy of a novel class of antagonists for d-methamphetamine self-administration. Although it is still relatively unknown how amphetamines increase DA levels in synaptic clefts, these findings suggest that development of VMAT2 inhibitors as a specific amphetamine antagonists in vivo is possible.
